Clinically, the degradation product of fibrin (fibrinogen) is an experiment to determine the function of fibrinolysis system. When the primary and secondary fibrinolytic activities increase, the content of fibrinogen degradation products in blood increases, and obvious precipitation peaks can appear. Fibrinogen degradation products mainly reflect the fibrinolytic function. Its growth is common in:
A) primary fibrinolysis hyperfunction;
B) Secondary fibrinolysis: hypercoagulable state, disseminated intravascular coagulation, kidney disease, organ transplant rejection, thrombolytic therapy, etc.
C) Vascular embolic diseases (pulmonary embolism, myocardial infarction, occlusive cerebrovascular disease, deep vein thrombosis);
D) After the induction period of leukemia chemotherapy, hemorrhagic thrombocytosis, uremia, liver disease or various tumors.